Dara raises $10M for drug launch; Mersana adds $4M to round; Amarin jumps on blockbuster hopes;

 @FierceBiotech: Medidata snags biz from rival Oracle in record Q1. Article | Follow @FierceBiotech

 @JohnCFierce: AstraZeneca says so long to half a billion dollars; formally ends Targacept depression deal. Story | Follow @JohnCFierce

 @RyanMFierce: Mersana has snagged $4M more for work on next-gen ADCs targeting cancer. More | Follow @RyanMFierce

 @MarkHFierce: Could the device tax hurt Minnesota's lead status as a med device employer? Trouble has already come, it seems. Article | Follow @MarkHFierce

> Dara BioSciences has raised $10.25 million through a stock sale. The company plans to use the money to launch two new cancer drugs. Story

> Cambridge, MA-based Mersana Therapeutics has filed SEC documents which show it raised an additional $4 million. Filing

> Shares of Amarin ($AMRN) jumped on Monday as analysts at Citi released new estimates showing that AMR101 could hit $2.6 billion in peak sales--provided the company strikes a partnership deal. Story

> Salix Pharma says that the FDA has extended its review of crofelemer by 90 days. The drug is designed to treat HIV-related diarrhea. Story

Pharma News

 @FiercePharma: Our latest and greatest ranking of highest-paid CEOs in pharma. Some you'd expect, some you wouldn't. Report | Follow @FiercePharma

> Abbott tries to throw up roadblock to Humira biosim. Story

> Avastin, Lucentis equally effective at improving vision, big study finds. More

Medical Devices News

@FierceMedDev: Scientific American: Four Medical Implants that Escaped FDA Scrutiny. News | Follow @FierceMedDev

> St. Jude, Edwards among those named as potential J&J M&A targets. Article

> Breast cancer risk test inches closer to reality. Story

> Hospira sees profits fall 73%. Item

> St. Jude touts safety of leads with Optim insulation. News

Biotech Research News

> Stay calm, folks: Highly anxious mice developed more aggressive cancer. Story

> U-M registers second stem cell line as research fight continues. News

> U.K. scientists map structure of crucial obesity receptor region. Article

> Cleveland Clinic researcher seeks funds to advance breast cancer vaccine into human trials. More

> Potential Alzheimer's treatment disrupts amyloid protein formation. Item

Pharma Manufacturing News

> BASF moves some production from Illinois to Germany. News

> Claris claims it has passed FDA plant inspection. Story

> Haemonetics, Pall ink $550M deal. Article

And Finally… A new study concludes that even as children make up the majority of patients in a wide range of diseases, they are rarely tested in clinical studies. Report

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.